Janice Reed

567 total citations
25 papers, 426 citations indexed

About

Janice Reed is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Janice Reed has authored 25 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 15 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Janice Reed's work include Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (9 papers) and Cancer Treatment and Pharmacology (7 papers). Janice Reed is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (9 papers) and Cancer Treatment and Pharmacology (7 papers). Janice Reed collaborates with scholars based in United States and Egypt. Janice Reed's co-authors include Mary Ann Karam, Rachid Baz, Beth Faiman, Esteban Walker, Mohamad A. Hussein, Gordan Srkalović, Megan Kelly, Steven Andrèsen, Toni K. Choueiri and Robert Knight and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Janice Reed

24 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janice Reed United States	10	307	271	220	71	32	25	426
Valentina Giai Italy	9	197 0.6×	127 0.5×	42 0.2×	132 1.9×	11 0.3×	24	287
Anna Christoforidou Greece	10	100 0.3×	65 0.2×	52 0.2×	55 0.8×	13 0.4×	29	227
Peter A. Forsberg United States	10	199 0.6×	137 0.5×	165 0.8×	30 0.4×	29 0.9×	40	359
M. Puntous France	11	220 0.7×	70 0.3×	95 0.4×	52 0.7×	4 0.1×	34	318
Vlatko Pejša Croatia	10	89 0.3×	61 0.2×	75 0.3×	129 1.8×	13 0.4×	39	264
Irene Ferreira Spain	7	156 0.5×	83 0.3×	157 0.7×	31 0.4×	116 3.6×	11	337
J. Catalano United Kingdom	9	127 0.4×	114 0.4×	68 0.3×	50 0.7×	8 0.3×	14	210
Yasufumi Matsuda Japan	10	65 0.2×	93 0.3×	70 0.3×	26 0.4×	6 0.2×	27	259
C B Begg United States	8	306 1.0×	96 0.4×	138 0.6×	72 1.0×	6 0.2×	9	415
Clemens Leitgeb Austria	8	548 1.8×	121 0.4×	208 0.9×	178 2.5×	2 0.1×	13	639

Countries citing papers authored by Janice Reed

Since Specialization

Citations

This map shows the geographic impact of Janice Reed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice Reed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice Reed more than expected).

Fields of papers citing papers by Janice Reed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice Reed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice Reed. The network helps show where Janice Reed may publish in the future.

Co-authorship network of co-authors of Janice Reed

This figure shows the co-authorship network connecting the top 25 collaborators of Janice Reed. A scholar is included among the top collaborators of Janice Reed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice Reed. Janice Reed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chakraborty, Rajshekhar, et al.. (2020). Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma. British Journal of Haematology. 189(6). 1136–1140. 22 indexed citations

Covut, Fahrettin, Christy Samaras, Faiz Anwer, et al.. (2019). External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood. 134(Supplement_1). 3148–3148. 1 indexed citations

Reed, Janice, et al.. (2019). Who Needs What? Perceptions of Patients and Caregivers in Oncology Phase 1 Trials. SHILAP Revista de lepidopterología. 7(1). 27–33. 15 indexed citations

Chakraborty, Rajshekhar, Lisa Rybicki, Janice Reed, et al.. (2019). Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma. Blood. 134(Supplement_1). 5566–5566. 2 indexed citations

Lee, Sarah S., Bhumika Patel, Mary Ann Karam, et al.. (2018). Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis. Blood. 132(Supplement 1). 2009–2009. 6 indexed citations

Khouri, Jack, Bicky Thapa, Frederic J. Reu, et al.. (2018). Daratumumab proves safe and highly effective in AL amyloidosis. British Journal of Haematology. 185(2). 342–344. 39 indexed citations

Reu, Frederic J., Dale Grabowski, Reda Z. Mahfouz, et al.. (2015). A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 33(15_suppl). 8584–8584. 2 indexed citations

Narkhede, Mayur, Jason Valent, Chad Cummings, et al.. (2014). Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy. Blood. 124(21). 2620–2620. 2 indexed citations

Horwitz, Leonard, Beth Faiman, Paul Elson, et al.. (2012). A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood. 120(21). 5045–5045. 1 indexed citations

10.

Lazaryan, Aleksandr, Rachid Baz, Mohamad A. Hussein, et al.. (2010). Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma. Blood. 116(21). 1967–1967. 1 indexed citations

11.

Lazaryan, Aleksandr, Alan Lichtin, Keith R. McCrae, et al.. (2010). Bortezomib for ITP: First Report of Successful Treatment of Refractory ITP In a Patient with Otherwise Asymptomatic Monoclonal Gammopathy. Blood. 116(21). 4667–4667. 3 indexed citations

12.

Baz, Rachid, Suzanne Fanning, Lori Kunkel, et al.. (2007). Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leukemia & lymphoma. 48(12). 2338–2344. 11 indexed citations

13.

Baz, Rachid, Esteban Walker, Mohamed A. Karam, et al.. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 17(12). 1766–1771. 116 indexed citations

14.

Hussein, Mohamad A., Rachid Baz, Gordan Srkalović, et al.. (2006). Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings. 81(7). 889–895. 84 indexed citations

15.

Abou-Jawde, Rony M., Janice Reed, Megan Kelly, et al.. (2006). Efficacy and Safety Results with the Combination Therapy of Arsenic Trioxide, Dexamethasone, and Ascorbic Acid in Multiple Myeloma Patients: A Phase 2 Trial. Medical Oncology. 23(2). 263–272. 33 indexed citations

16.

Abou-Jawde, Rony M., Rachid Baz, Esteban Walker, et al.. (2006). The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.. PubMed. 91(10). 1410–3. 24 indexed citations

17.

Baz, Rachid, Megan Kelly, Janice Reed, et al.. (2006). Phase II study of dexamethasone, ascorbic acid, thalidomide and arsenic trioxide (DATA) in high risk previously untreated (PU) and relapsed/refractory (RR) multiple myeloma (MM). Journal of Clinical Oncology. 24(18_suppl). 17535–17535. 3 indexed citations

18.

Almhanna, Khaldoun, Rachid Baz, Mary Ann Karam, et al.. (2005). Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).. Blood. 106(11). 2557–2557. 4 indexed citations

19.

Walker, Esteban, Khaldoun Almhanna, Steve Andresen, et al.. (2005). Full Dose Vincristine (V) Negatively Impacts Progression Free Survival in Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Treated with Pegylated Doxorubicin, Vincristine, Reduced-Dose Dexamethasone, and Thalidomide (DVd-T).. Blood. 106(11). 2570–2570. 1 indexed citations

20.

Hussein, Mohamad A., Mary Ann Karam, C. Brand, et al.. (2004). Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.. Blood. 104(11). 208–208. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact